Colorectal Cancer

CheckMate 9X8 trial results indicate a progression-free survival improvement with nivolumab that was not statistically significant.

Promising study results support continued research of T-DXd in patients with HER2-positive mCRC while the risk of potential ILD/pneumonitis requires monitoring.

Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.

In a phase 1/2 study demonstrated that the combination of encorafenib, cetuximab, and nivolumab was well tolerated and led to responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Results from a large trial evaluating the combination of pembrolizumab and regorafenib showed durable results for patients with microsatellite stable colorectal cancer.

Treatment with a triplet combination of pembrolizumab, binimetinib and bevacizumab was associated with an observed clinical benefit in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

Phase 1b/2 data for the combination of onvansertib with FOLFIR I and bevacizumab appear promising for paints with KRAS-mutant metastatic colorectal cancer.

Sotorasib produced an objective response rate of 9.7% in patients with colorectal cancer.

With an increase in genomic testing for colorectal cancer, new targeted treatments have also been developed to treat patients with specific disease characteristics.

Results from the phase 1b CodeBreak 101 study were favorable for the combination of sotorasib and trametinib in patients with colorectal cancer and non–small cell lung cancer.

After 40 years, a novel agent may be on the fast track to becoming the first drug to improve the standard of care for patients with metastatic colorectal cancer.

Results from the phase 3 AGENT study are awaited after the FDA granted fast track designation to arfolitixorin for advanced colorectal cancer treatment.

TheADAGE study has shown that in both young and older patients, chemotherapy is manageable in the adjuvant setting.

Mary F. Mulcahy discusses the potential implications of the EPOCH trial in clinical practice.

Dr Mary Mulcahy, a key opinion leader, describes the efficacy and safety outcomes of the EPOCH clinical trial.

Dr Mary Mulcahy explains the rationale and study design of the phase III EPOCH clinical trial.

Dr Mary Mulcahy, an expert oncologist, details how radioembolization is involved in the treatment of colorectal cancer with liver metastasis.

A recently published study has shown no difference in survival outcomes for patients under 50 with colorectal cancer, despite greater treatment intensity and physical fitness.

Mary F. Mulcahy, MD, describes the treatment options available for colorectal cancer with liver metastasis in the first and second line.

The primary end point of the phase 3 SOLSTICE study of trifluridine and tipiracil plus bevicizumab versus capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer was not met.

An expert breaks down therapy sequencing in metastatic colorectal cancer and provides some clinical pearls.

Kanwal Raghav, MBBS, MD, explains the rationale for using regorafenib for metastatic colorectal cancer and reviews data from 2 clinical trials.

An oncologist reviews the maintenance therapy options in metastatic colorectal cancer and what clinical findings can lead to a change in therapies.

Kanwal Raghav, MBBS, MD, presents the case of a 72-year-old woman with metastatic colorectal cancer and describes the first-line therapy options.

The last patient has been enrolled in the phase 2 MOUNTAINEER trial, evaluating tucatinib both as a monotherapy and in combination with trastuzumab for the treatment of HER2-positive metastatic colorectal cancer following previous first- and second-line standard of care therapies.